Freeze-dried matrices for ocular administration of bevacizumab: a comparison between subconjunctival and intravitreal administration in rabbits
- 24 Downloads
This work was aimed to tune solid matrices for bevacizumab (BVZ) subconjunctival or intravitreal administration in order to prolong drug release, to reduce the number of applications and consequently the side effects. Matrices, with sizes suitable for intravitreal or subconjunctival administration, based on hydroxypropylmethyl cellulose (HPMC), polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA) and polyacrylic acid (PAA) were obtained by freeze-drying of polymeric dispersions either in phosphate buffer solution or water and were sterilized by gamma rays. The matrices were characterized from the technological point of view and evaluated for in vitro release of dextran and BVZ. In vivo evaluation of BVZ release in ocular humours was finally carried out on rabbits. The obtained matrices showed solvent sorption time ranging from a few seconds for PAA to 46 min for HPMC, with shorter times when prepared in buffer solution. The hydration times were up to 5.5-fold higher after sterilization. HPMC and PVA matrices showed a slowdown of the release rate of both dextran and BVZ, but HPMC was selected for following in vivo studies also in consideration of its higher viscosity after rehydration of the matrix. HPMC matrix was well tolerated by the rabbit eye when intravitreally and subconjunctivally administered. The different treatment produced the same effect in terms of drug concentration in aqueous and vitreous humour up to 12 weeks after administration. The results of this study support the possible use of lyophilized matrices as a BVZ delivery system to the posterior segment of the eye.
KeywordsBevacizumab Subconjunctival Intravitreal Rabbit Freeze-drying Matrices
This work was funded by University of Pisa (grant PRA 2016_27). The authors would like to thank Dr. Carla Lenzi and Prof. Giancarlo De Montis for technical support to histological analysis and the relevant interpretation of the results.
Compliance with ethical standards
All institutional and national guidelines for the care and use of laboratory animals were followed.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Agarwal A, Rhoades WR, Hanout M, Soliman MK, Sarwar S, Sadiq MA, et al. Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development. Clin Ophthalmol. 2015; https://doi.org/10.2147/OPTH.S74959.
- 2.World Health Organization. Action plan for the prevention of avoidable blindness and visual impairment 2009-2013, vol. 2010. Geneva: WHO Document Production Services.Google Scholar
- 10.Dow Brochure, ID 1051. Dow Chemical Company; 2015. https://dowac.custhelp.com/app/answers/detail/a_id/1051/related/1.
- 17.Sahoo CK, Rao SRM, Sudhaka M. HPMC a biomedical polymer in pharmaceutical dosage forms. J Chem Pharm Sci. 2015;8:875–81.Google Scholar
- 19.Sharma G, Khalili A, Awwad S, Malik K, Matejtschuk P, Gaisford S, et al. Freeze drying to develop a bevacizumab-based tablet for ocular implantation. Invest Ophthalmol Vis Sci. 2013;54:Abstract 1082.Google Scholar
- 20.Sousa F, Cruz A, Fonte P, Mendes Pinto I, Neves-Petersen MT, Sarmento B. A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles. Sci Rep. 2017:2017. https://doi.org/10.1038/s41598-017-03959-4.
- 23.Cleland JL, Lam X, Kendrick B, Yang J, Yang TH, Overcashier D, et al. A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci. 2001;90:310–21. https://doi.org/10.1002/1520-6017(200103)90:3<310::AID-JPS6>3.0.CO;2-R.CrossRefPubMedGoogle Scholar
- 25.Silindir M, Ozer AY. Sterilization methods and the comparison of E-beam sterilization with gamma radiation sterilization. FABAD J Pharm Sci. 2009;34:43–53.Google Scholar
- 26.Abrishami M, Ganavati SZ, Soroush D, Rouhbakhsh M, Jaafari MR, Malaekeh-Nikouei B. Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (Avastin) for intravitreal administration. Retina. 2009;29:699–703. https://doi.org/10.1097/IAE.0b013e3181a2f42a.CrossRefPubMedGoogle Scholar
- 30.Sinapis CI, Routsias JG, Sinapis AI, Sinapis DI, Agrogiannis GD, Pantopoulou A, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. Clinical Ophthalmol. 2011; https://doi.org/10.2147/OPTH.S19555.
- 31.Ye Z, Ji YL, Ma X, Wen JG, Wei W, Huang SM. Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits. Int J Ophthalmol. 2015; https://doi.org/10.3980/j.issn.2222-3959.2015.04.02.
- 35.Pandit J, Sultana Y, Aqil M. Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. Art Cells Nanomed Biothechnol. 2017;45:1397–407. https://doi.org/10.1080/21691401.2016.1243545.CrossRefGoogle Scholar